Differential and shared genetic effects on kidney function between diabetic and non-diabetic individuals
Winkler, T.W. ; Schulz, C.-A. LU ; Orho-Melander, M. LU ; Melander, O. LU
and Heid, Iris M.
(2022)
In Communications Biology
5(1).
- Abstract
- Reduced glomerular filtration rate (GFR) can progress to kidney failure. Risk factors include genetics and diabetes mellitus (DM), but little is known about their interaction. We conducted genome-wide association meta-analyses for estimated GFR based on serum creatinine (eGFR), separately for individuals with or without DM (nDM = 178,691, nnoDM = 1,296,113). Our genome-wide searches identified (i) seven eGFR loci with significant DM/noDM-difference, (ii) four additional novel loci with suggestive difference and (iii) 28 further novel loci (including CUBN) by allowing for potential difference. GWAS on eGFR among DM individuals identified 2 known and 27 potentially responsible loci for diabetic kidney disease. Gene prioritization highlighted... (More)
- Reduced glomerular filtration rate (GFR) can progress to kidney failure. Risk factors include genetics and diabetes mellitus (DM), but little is known about their interaction. We conducted genome-wide association meta-analyses for estimated GFR based on serum creatinine (eGFR), separately for individuals with or without DM (nDM = 178,691, nnoDM = 1,296,113). Our genome-wide searches identified (i) seven eGFR loci with significant DM/noDM-difference, (ii) four additional novel loci with suggestive difference and (iii) 28 further novel loci (including CUBN) by allowing for potential difference. GWAS on eGFR among DM individuals identified 2 known and 27 potentially responsible loci for diabetic kidney disease. Gene prioritization highlighted 18 genes that may inform reno-protective drug development. We highlight the existence of DM-only and noDM-only effects, which can inform about the target group, if respective genes are advanced as drug targets. Largely shared effects suggest that most drug interventions to alter eGFR should be effective in DM and noDM. © 2022, The Author(s). (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1205e2b3-854a-4478-a0c8-3aaec3cab222
- author
- Winkler, T.W.
; Schulz, C.-A.
LU
; Orho-Melander, M.
LU
; Melander, O.
LU
and Heid, Iris M.
- author collaboration
- organization
- publishing date
- 2022
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- creatinine, diabetes mellitus, diabetic nephropathy, genetics, genome-wide association study, glomerulus filtration rate, human, kidney, Creatinine, Diabetes Mellitus, Diabetic Nephropathies, Genome-Wide Association Study, Glomerular Filtration Rate, Humans, Kidney
- in
- Communications Biology
- volume
- 5
- issue
- 1
- article number
- 580
- publisher
- Nature Publishing Group
- external identifiers
-
- scopus:85131867525
- pmid:35697829
- ISSN
- 2399-3642
- DOI
- 10.1038/s42003-022-03448-z
- language
- English
- LU publication?
- yes
- id
- 1205e2b3-854a-4478-a0c8-3aaec3cab222
- date added to LUP
- 2022-09-12 10:56:13
- date last changed
- 2024-01-18 14:16:29
@article{1205e2b3-854a-4478-a0c8-3aaec3cab222,
abstract = {{Reduced glomerular filtration rate (GFR) can progress to kidney failure. Risk factors include genetics and diabetes mellitus (DM), but little is known about their interaction. We conducted genome-wide association meta-analyses for estimated GFR based on serum creatinine (eGFR), separately for individuals with or without DM (nDM = 178,691, nnoDM = 1,296,113). Our genome-wide searches identified (i) seven eGFR loci with significant DM/noDM-difference, (ii) four additional novel loci with suggestive difference and (iii) 28 further novel loci (including CUBN) by allowing for potential difference. GWAS on eGFR among DM individuals identified 2 known and 27 potentially responsible loci for diabetic kidney disease. Gene prioritization highlighted 18 genes that may inform reno-protective drug development. We highlight the existence of DM-only and noDM-only effects, which can inform about the target group, if respective genes are advanced as drug targets. Largely shared effects suggest that most drug interventions to alter eGFR should be effective in DM and noDM. © 2022, The Author(s).}},
author = {{Winkler, T.W. and Schulz, C.-A. and Orho-Melander, M. and Melander, O. and Heid, Iris M.}},
issn = {{2399-3642}},
keywords = {{creatinine; diabetes mellitus; diabetic nephropathy; genetics; genome-wide association study; glomerulus filtration rate; human; kidney; Creatinine; Diabetes Mellitus; Diabetic Nephropathies; Genome-Wide Association Study; Glomerular Filtration Rate; Humans; Kidney}},
language = {{eng}},
number = {{1}},
publisher = {{Nature Publishing Group}},
series = {{Communications Biology}},
title = {{Differential and shared genetic effects on kidney function between diabetic and non-diabetic individuals}},
url = {{http://dx.doi.org/10.1038/s42003-022-03448-z}},
doi = {{10.1038/s42003-022-03448-z}},
volume = {{5}},
year = {{2022}},
}